beta-(-4 Chlorophenyl) GABA (baclofen) inhibits prolactin and thyrotropin release by acting on the rat brain

Baclofen, a GABA B agonist, inhibits prolactin release due to different kinds of stress. In the present study its effect was evaluated in several endocrine experimental situations to explore the specificity of this effect, as well as the site of action of the drug. Baclofen significantly inhibited prolactin and thyrotropin outputs induced by 25 min of suckling, without altering milk ejection or LH secretion. The effect was also tested in median eminence-lesioned rats and in in vitro incubations. Baclofen did not modify prolactin levels in rats in which brain control of the pituitary secretion was eliminated by destruction of the median eminence, and it did not inhibit prolactin or thyrotropin secretion from incubated hemipituitaries. It is postulated that baclofen inhibits prolactin and thyrotropin secretion by acting on GABA B receptors related to the brain control of pituitary secretion.     

II. Effect of aminooxyacetic acid and bicuculline on prolactin release in castrated male rats

To investigate the role of gamma aminobutyric acid (GABA) on prolactin secretion, castrated male rats were infused with aminooxyacetic acid (AOAA) or bicuculline, two drugs that affect GABA metabolism or its binding to the receptors, respectively. The infusion of AOAA or bicuculline for 2 hr did not significantly modify serum prolactin levels. A quick iv injection of sulpiride, a drug that induces hyperprolactinemia, brought about a significantly lower release of prolactin in rats infused with AOAA than in control rats, infused with saline. The response to sulpiride in rats infused with bicuculline was significantly greater, in terms of prolactin release, than in control rats. These results suggest that GABA may have an inhibitory role on the regulation of prolactin release.     

Size heterogeneity of pituitary and plasma prolactin: Effect of chronic estrogen treatment

Pituitary homogenates and plasma from untreated and estrogen treated ovariectomized rats were subjected to gel filtration chromatography and the prolactin in fractions collected between the void and total elution volumes of the columns was determined by radio- immunoassay. Three components of prolactin, identified as “void volume”, “big” and “little” according to increasing elution volumes, were observed in pituitary homogenates of ovariectomized rats. These three components accounted for 4, 11 and 85% of the total prolactin activity respectively. Estrogen treatment of ovariectomized rats increased the total prolactin in the pituitary and also selectively increased the “big” component to 21% of the prolactin activity on the column. A smaller increase was also observed in the “void volume” component. Gel filtration of the plasma obtained from estrogen-treated rats before and during the estrogen-induced afternoon surge of prolactin showed that “little” prolactin was the predominate form being secreted and that the “void volume” and “big” components were also released. The release of the components was not in proportion to that observed in the pituitary and the larger components were released in a nonuniform manner. The “void volume” component appeared in the plasma as the surge began but then disappeared as the “big” component appeared at the peak of the surge. The big component decreased as the surge waned leaving primarily “little” component in plasma. The data indicate (1) that estrogen stimulates the formation of the larger components of prolactin in the pituitary (2) that the types of prolactin released into plasma of estrogen-treated ovariectomized rats is not in proportion to that found in the pituitary and (3) that the heterogeneous forms of prolactin are selectively released into plasma during the prolonged secretory episode of the afternoon surge of prolactin induced by estrogen.     

Purification of a non-dopaminergic and non-GABAergic prolactin release-inhibiting factor (PIF) in sheep stalk-median eminence

Prolactin release-inhibiting factor (PIF) extracted from 1200 sheep stalk-median eminences was purified by gel filtration on a Sephadex G-25 column (4.5 X 150 cm). PIF activity was determined by measuring the inhibition of prolactin release from dispersed anterior pituitary cells of adult male or estrogen-primed, ovariectomized rats. Using this system, PIF was detected in tube fractions 122-127 (volume = 20 ml/tube). These fractions also contained LHRH and somatostatin; however, these peptides had no prolactin-inhibiting activity in the quantities present. No dopamine or gamma-aminobutyric acid (GABA) was detected in the active fractions by radioenzymatic assay and fluorophotoenzymatic assay, respectively. Furthermore, receptor blockers for dopamine or GABA did not interfere with the PIF activity. These findings indicate that the PIF activity cannot be attributed to either dopamine or GABA, both of which are known to inhibit prolactin release, and provide evidence for the presence of a non-dopaminergic and non-GABAergic PIF within the hypothalamus.     

Temporal dynamics of pituitary prolactin depletion and release in three strains of rats.

Previous reports have shown that pituitary prolactin is rapidly transformed to a less soluble, but much more releasable, form prior to release from the lactotroph. One manifestation of this transformation is that pituitary prolactin depletion is significantly greater than concurrent release both in vivo and in vitro. The objective of this study was to compare the magnitude and temporal dynamics of depletion and release from pituitaries of ovariectomized estrogen-treated rats of three different strains in vitro to assess the effect of strain on the transformation process. Mature ovariectomized Wistar-Furth (WF), Sprague-Dawley (SD) and Long-Evans (LE) rats (7-10/group) were killed by decapitation 7 days after a single s.c. injection of 100 micrograms of polyestradiol phosphate. The anterior pituitaries were quickly removed and cut into quarters which were incubated for up to 4 hrs in the absence of dopamine or other prolactin secretagogues. Representative fragments from each strain were not incubated but were snap frozen to measure pre-incubation content. Fragments from each strain were removed from incubation at 30, 60, 120, 180 and 240 min for prolactin content measurement. Medium was collected at 30 min intervals and replaced with fresh medium. The experiments were repeated twice. Prolactin in medium and pituitary homogenates was measured by radioimmunoassays using NIAMDD-RP-1 as standard. In all three stains release of prolactin was approximately 30-50% of the prolactin depleted from the pituitary in 4 hrs. Strains varied in the magnitude of this difference and the time course over which it occurred. WF and SD rats showed significantly greater depletion and release of prolactin than did LE rats when the data were expressed as micrograms prolactin/mg pituitary. When the data were expressed as a percentage of prolactin available for release, the differences in depletion between strains disappeared and the LE rats released a significantly greater percentage of the prolactin available for release than did the other two strains. We conclude that pituitary prolactin undergoes a process of transformation prior to release which causes it to disappear from the pituitary but not appear in culture medium. We further conclude that the magnitude and temporal dynamics of this process are not equivalent across all strains of rats.     

The effects of estradiol on pituitary responsiveness to dopamine in vitro: a comparison of ovariectomized Fischer 344 and Holtzman rats.

The objective of this study was to determine if the effectiveness of dopamine as an inhibitor of prolactin is altered by estradiol in strains of rats which show marked differences in estrogen-induced pituitary hyperplasia. Groups of Fischer 344 and Holtzman Sprague-Dawley rats were ovariectomized and implanted with Silastic capsules of estradiol. Rats were sacrificed by rapid decapitation following a brief period of ether anesthesia at 2, 4, 6, 8 weeks (F-344) or at 2 and 8 weeks (Holtzman) of estradiol treatment. The pituitary was removed and cut into fragments which were either snap frozen for initial prolactin content measurements or incubated for 60 min in the presence or absence of dopamine (1 x 10(-6) M). Prolactin was measured in the plasma, in sonicates of the pituitary and in the incubation medium by double antibody radioimmunoassay. Pituitary weight and plasma levels of prolactin were significantly less in Holtzman rats compared to Fischer 344 females at 2 or 8 weeks of estradiol treatment but pituitary concentrations of prolactin were not different between the two strains. Pituitary fragments from Fischer 344 rats studied at 2 and 4 weeks of estradiol treatment did not respond to the removal of dopamine in vitro whereas pituitary fragments from Holtzman rats obtained at 2 weeks of estradiol treatment did release significantly more prolactin in the absence than in the presence of dopamine. Pituitary fragments taken from Fischer 344 rats at 6 and 8 weeks were responsive to dopamine whereas pituitary tissue from Holtzman rats was not responsive at 8 weeks. The data indicate that temporal differences in responsiveness to the inhibitory effects of dopamine occur in strains which are susceptible or resistant to the formation of pituitary tumors following prolonged estradiol treatment.     

Tachykinins and the control of prolactin secretion

Tachykinins are present in the pituitary gland and in brain areas involved in the control of the secretion of pituitary hormones. Tachykinins have been demonstrated to stimulate prolactin release acting directly on the anterior pituitary gland. These peptides have also been revealed to be able to act at the hypothalamic level, interacting with neurotransmitters and neuropeptides that have the potential to affect prolactin secretion. Tachykinins seem to act by stimulating or inhibiting the release of the factors that affect prolactin secretion. Among them, tachykinins have been demonstrated to stimulate oxytocin and vasopressin release, which in turn results in prolactin release. Tachykinins also potentiated the response to vasoactive intestinal peptide (VIP) and reinforced the action of glutamate, which in turn result in prolactin release. They have also been shown to interact with serotonin, a neurotransmitter involved in the control of prolactin secretion. In addition, tachykinins have been shown to inhibit GABA release, a neurotransmitter with prolactin-release inhibiting effect. This inhibition may result in an increased prolactin secretion by removal of the GABA inhibition. On the other hand, tachykinins have also been shown to stimulate dopamine release by the hypothalamus, an action that results in an inhibition of prolactin release. Dopamine is a well known inhibitor of prolactin secretion. In conclusion, although tachykinins have been shown to have a predominantly stimulatory effect on prolactin secretion, especially at the pituitary level, under some circumstances they may also exert an inhibitory influence on prolactin release, by stimulating dopamine release at the hypothalamic level.     

The effect of pituitary homografts on the accessory sex organs and serum hormonal levels with or without androgen in mature male rats

The effect of pituitary homografts on the accessory sex organs and hormonal levels were studied in Wistar mature male rats. Grafted rats were further divided into four experiments: rats were bled once daily via a jugular vein cannula for seven days to investigate when serum prolactin began to rise after transplantation. rats were decapitated on the seventh day after transplantation to test whether 7 days were long enough to show the effect of pituitary grafts on the weight of prostate and seminal vesicles. rats were orchiectomized or orchiectomized and adrenalectomized on the seventh day after transplantation and then decapitated 4 weeks later to test a long term action of pituitary grafts and hormonal levels on the accessory sex organs without androgen. Rats grafted with several pieces of muscle were used as controls in each experiment. The initial rise in serum prolactin level was observed on the fourth day after pituitary transplantation, and then a higher serum prolactin level was maintained thereafter. Despite the higher prolactin level in the pituitary-grafted rat than in the control, no significant differences from the control in the weight of prostates and seminal vesicles and adrenal gland and the concentrations of serum luteinizing hormone (LH) and follicular stimulating hormone (FSH) were measured. This result showed that the weight of accessory sex organs was not affected by a higher serum prolactin within seven days.(ABSTRACT TRUNCATED AT 250 WORDS)     

Inhibitory effects of substance P on the gamma-amino-butyric acid and gamma-hydroxybutyric acid-induced growth hormone and prolactin release in male rats

Gamma-aminobutyric acid (GABA) at 50 μg/10 μ1 was injected into the lateral ventricle after pretreatment with intraventricular injection of 1 μg of substance P in urethane anesthetized male rats. Thirty minutes after GABA injection the animals were decapitated and blood samples were collected from the trunk. Serum GH and prolactin were determined by radioimmunoassays. The intraventricular GABA elicited a significant increase in both serum GH and prolactin levels. Intraventricular substance P itself had no effect on serum GH and prolactin, but it inhibited the GABA-induced increases in serum GH and prolactin. Gamma-hydroxybutyric acid (GHB) was intraperitoneally injected with and without an intraventricular injection of substance P in urethane anesthetized rats. The GHB injection significantly increased serum GH and prolactin levels. Pretreatment with substance P completely inhibited the GHB-induced GH and prolactin responses. These results suggest that substance P might interact with GABA in the central nervous system.     

Possible role of prolactin in growth regulation

To study the possible role of prolactin on growth regulation pituitary grafted rats of different ages and their sham-operated controls have been used. After the transplant operation of one pituitary gland from a litter-mate donor on day 5 or on day 30 of life, a marked prolactin increase has been observed. This increase has been immediate in 30 day-old rats and delayed in 5 day-old rats in which the elevation starts being significant on day 20 for females and on day 25 for male rats. Pituitary grafting on day 5 of life, with an adult donor gland, resulted in an immediate and marked increase of prolactin values in both sexes. Litter-mate donor pituitary grafting, on day 5 of life, resulted in an increase in body weight that could be directly correlated with the increase in prolactin levels. Adult pituitary grafting resulted in an increased body weight in females with no effects being detected in males. In 30 day-old grafted male and female rats, marked body weight increases were seen, over the whole studied period, together with an increase in nose-tail length (1 cm in female and 1.5 cm in males longer than the control animals). All these changes do not seem not be related to GH modifications in pituitary grafted rats, since GH changes were very slight with a final tendency to lower values in female rats but not in males. All these data could suggest that prolactin might exert a direct effect on growth both in male and female rats.(ABSTRACT TRUNCATED AT 250 WORDS)     

GABAergic control of anterior pituitary hormone secretion

Anatomical and biochemical studies have identified a hypothalamic tubero-infundibular GABAergic system, which plays a functional role on anterior pituitary hormone secretion. Experimental and clinical evidence support the presence of a dual component in the action of GABA; one mediated via the central nervous system and the other exerted directly at the anterior pituitary level. The two sites of action may be responsible for the excitatory and inhibitory effects of GABA on pituitary hormone and especially prolactin secretion. The future characterization of this system will provide a better understanding of the involvement of GABA in the physiology of anterior pituitary hormone secretion and will contribute to the development of new pharmacological agents for the therapy of neuroendocrine disorders.     

Comparison of efficacy of cysteamine in depleting prolactin immunoreactivity in different hyperprolactinemic animal models

We have examined the effects of cysteamine on its ability to deplete prolactin in various states of hyperprolactinemia. Administration of subtoxic doses of cysteamine (75 and 150 mg/kg,sc) dramatically reduces serum prolactin levels as well as pituitary prolactin content in a dose-dependent manner in estrogen-primed brown Irish ACI female rats. A similar dose-dependent decrease in anterior pituitary prolactin levels was observed in two ectopic prolactin secreting pituitary tumor models (MtTW15 and 7315a). However, a significant reduction in serum prolactin levels was seen in these same tumor bearing animals at only the 150 mg/kg dose of cysteamine. Interestingly, the prolactin content of each of the prolactin secreting tumors, although reduced by cysteamine administration, the effect was neither dose-dependent nor as dramatic as that observed in the anterior pituitary gland proper. These data demonstrate that cysteamine can significantly lower prolactin concentrations in hyperprolactinemia. Further, ectopic prolactin secreting pituitary tissue appears less sensitive to the prolactin-depleting effects of cysteamine. This latter finding may explain, in part, why serum prolactin levels were not as severely reduced in the ectopic tumor bearing female rats as in estrogen-induced hyperprolactinemic animals.     

Evidence for an inhibitory influence of rat placental lactogen on prolactin release in vitro

Incubation of placental tissue from Day 11 pregnant rats for increasing periods of time resulted in proportionately more rat placental lactogen (rPL) release. The amount of placental tissue incubated correlated directly with the amount of rPL released into the medium. When placentas were coincubated with anterior pituitaries from ovariectomized rats, prolactin release was significantly inhibited. When media from incubations which had contained varying numbers of Day 11 placentas for 24 h were added to vials containing anterior pituitaries, prolactin release was inhibited, proportionate to the amount of rPL in the media. Media from incubations of Day 9 placentas, which contained very little rPL, had no effect on prolactin release. When medium containing anterior pituitary tissue was incubated for 24 h, pituitaries removed, and the medium incubated with placental tissue for an additional 24 h, there was no difference in prolactin levels compared to incubation medium not containing placental tissue. Addition of a trypsin inhibitor to the medium containing placental tissue did not augment the amount of prolactin remaining after a 24-h incubation. Thus it would appear that the placenta does not release a substance into the medium that destroys prolactin. This suggests that secretions from the placenta, presumably rPL, can exert a negative feedback on prolactin secretion at the level of the anterior pituitary.     

Possible role of glutamate, aspartate, glutamine, GABA or taurine on cadmium toxicity on the hypothalamic pituitary axis activity in adult male rats

This work was designed to evaluate the possible changes in glutamate, aspartate, glutamine, GABA and taurine within various hypothalamic areas the striatum and prefrontal cortex after oral cadmium exposure in adult male rats, and if these changes are related to pituitary hormone secretion. The contents of glutamine, glutamate, aspartate, GABA and taurine in the median eminence, anterior, mediobasal and posterior hypothalamus, and in prefrontal cortex in adult male rats exposed to 272.7 mol l^–1 of cadmium chloride (CdCl₂) in the drinking water for one month. Cadmium diminished the content of glutamine, glutamate and aspartate in anterior hypothalamus as compared to the values found in the untreated group. Besides, there is a decrease in the content of glutamate, aspartate and taurine in the prefrontal cortex. The amino acids studied did not change in median eminence, mediobasal and posterior hypothalamus or the striatum by cadmium treatment. Plasma prolactin and LH levels decreased in rats exposed to the metal. These results suggest that (1) cadmium differentially affects amino acid content within the brain region studied and (2) the inhibitory effect of cadmium on prolactin and LH secretion may be partially explained by a decrease in the content of both glutamate and aspartate in anterior hypothalamus, but not through changes in GABA and taurine.     

Growth hormone and prolactin content of hyperplastic anterior pituitary of dehydroepiandrosterone treated rats.

30 days after implantation of 80 mg dehydroepiandrosterone (androst-5-en-3betaol-17-one) hyperplastic enlargement of the anterior pituitary has been observed in about 80 per cent of the female rats. There was an important increase of prolactin content, growth hormone content remained unchanged. The mentioned alterations were found to be reversible, since regression was observed after DEA treatment exceeding 30 days. In females developing no hyperplasia pituitary growth hormone contentration and content has been decreased, prolactin content remained unchanged. In male rats on identical treatment no change of pituitary weight, growth hormone and prolactin concent has been found. The results suggest that, under physiological conditions, DEA does not affect pituitary growth hormone and prolactin content, however response to pharmacological doses was different in male and female rats.     

Mechanisms of precocious puberty induced in male rats by pituitary grafts

Male rats were grafted on Day 21 of age with 'young' (21 days old) or 'adult' (90 days old) pituitary glands and then treated daily with 4 mg bromocriptine/kg or vehicle. Plasma samples were obtained on Days 21, 25 and 35 and when balano-preputial separation occurred. Both types of grafts advanced the age at which balano-preputial separation occurred and increased prolactin concentrations. Bromocriptine treatment reduced the prolactin values in both grafted groups, but did not block the advancement of puberty in rats treated with 'young' pituitary grafts. These results suggest the existence of two possible mechanisms in precocious puberty induced by pituitary grafts: one is prolactin-dependent (when 'adult' pituitary glands were used) and the other not directly related to prolactin (when 'young' pituitary glands were used).     

On the mechanism by which dopamine inhibits prolactin release in the anterior pituitary

An $\text{in}$$\text{vitro}$ perfusion system was used to assess the effects of chloride channel blockers, dopamine (DA) receptor agonists and antagonists, and GABA receptor agonists and antagonists on prolactin release from the mouse anterior pituitary. Dopamine and muscimol inhibited prolactin release ($\text{IC}{}_{50}{}^1\text{= 6 × 10}{}^{\mathrm{?8}}\text{M and}\text{10}{}^{\mathrm{?5}}\text{M}$ respectively). The GABA receptor antagonist bicuculline blocked the inhibition of prolactin release by muscimol but not dopamine. The dopamine receptor antagonist chlorpromazine blocked the dopamine- but not muscimol-induced inhibition of prolactin release. Haloperidol, however, reversed both the muscimol and dopamine induced inhibition of prolactin release. Furthermore, the chloride channel blocker picrotoxinin blocked the inhibition of prolactin release elicited by both dopamine and muscimol. These later results suggest that the anterior pituitary dopamine receptor which mediates the inhibition of prolactin release may be coupled to a picrotoxinin sensitive chloride ionophore and that haloperidol may affect the function of both DA and GABA receptors in the anterior pituitary.     

Modifications of plasma prolactin levels and catecholamine content in an ectopic anterior pituitary gland transplanted under the kidney capsule

In order to study the possible role on prolactin secretion of the catecholamines present in ectopic pituitaries, female rats bearing an anterior pituitary graft under the kidney capsule since day 30 of life and their sham-operated controls, were sacrificed at 1, 2, 4, 7, 15, 30, 45 and 60 days after the operation. Data obtained showed a significant increase in plasma prolactin levels in grafted rats versus controls from the 4th day on after the grafting (p less than 0.01) until the 60th day (p less than 0.001). Dopamine content in the ectopic pituitary of grafted rats was higher than in their own in situ pituitaries or on those of sham-operated rats until day 45 being similar to them afterwards. Norepinephrine was also present in the pituitary graft but was not detected in the in situ pituitaries. The grafting of an anterior pituitary gland in an ectopic location was able to induce changes in the local catecholaminergic control of the prolactin secretion.     

Effect of passive immunization against substance P in rats with hyperprolactinemia

Substance P, an undecapeptide isolated from gut and brain tissues, was reported to stimulate prolactin release. It was suggested that substance P may play a role in the control of prolactin secretion. In this investigation we studied the effects of the blockade of endogenous substance P by the administration of a specific anti-substance P serum on serum prolactin levels in rats in the evening of proestrus, in lactating rats after suckling, and in male rats with hyperprolactinemia induced by grafting 2 anterior pituitary glands under the kidney capsule. The injection of the anti-substance P serum was followed by a significant decrease of the prolactin surge induced by 30 min suckling in lactating rats, when the antiserum was administered 24 hr but not 5.30 hr earlier. Anti-substance P serum also induced a significant decrease in serum prolactin levels in pituitary grafted rats, but induced no change in the proestrous surge of prolactin and LH. These results show that substance P may be involved in the release of prolactin induced by suckling and that this peptide may have an intrapituitary role in the process of prolactin release. On the other hand, substance P does not seem to play a significant role in the proestrous peak of prolactin and LH.